Marshall Wace North America L.P. grew its holdings in Danaher Co. (NYSE:DHR) by 48.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,115,438 shares of the conglomerate’s stock after purchasing an additional 690,837 shares during the quarter. Danaher comprises approximately 2.0% of Marshall Wace North America L.P.’s portfolio, making the stock its 5th largest holding. Marshall Wace North America L.P.’s holdings in Danaher were worth $279,281,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Marshall Wace LLP raised its position in shares of Danaher by 2,030.0% during the 1st quarter. Marshall Wace LLP now owns 120,175 shares of the conglomerate’s stock valued at $15,865,000 after buying an additional 114,533 shares during the period. Belpointe Asset Management LLC purchased a new stake in shares of Danaher during the 1st quarter valued at approximately $182,000. Kayne Anderson Rudnick Investment Management LLC raised its position in shares of Danaher by 18.2% during the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 190,170 shares of the conglomerate’s stock valued at $25,106,000 after buying an additional 29,217 shares during the period. AQR Capital Management LLC raised its position in shares of Danaher by 2.7% during the 1st quarter. AQR Capital Management LLC now owns 2,612,082 shares of the conglomerate’s stock valued at $340,981,000 after buying an additional 69,138 shares during the period. Finally, Mission Wealth Management LP raised its position in shares of Danaher by 5.3% during the 1st quarter. Mission Wealth Management LP now owns 10,540 shares of the conglomerate’s stock valued at $1,391,000 after buying an additional 530 shares during the period. 78.93% of the stock is currently owned by institutional investors and hedge funds.
In related news, CEO Thomas Patrick Joyce, Jr. sold 183,878 shares of Danaher stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $131.30, for a total value of $24,143,181.40. Following the completion of the sale, the chief executive officer now owns 302,377 shares in the company, valued at approximately $39,702,100.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP William King sold 12,950 shares of Danaher stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $129.92, for a total transaction of $1,682,464.00. Following the completion of the sale, the senior vice president now owns 29,070 shares of the company’s stock, valued at approximately $3,776,774.40. The disclosure for this sale can be found here. Insiders sold a total of 453,448 shares of company stock valued at $59,724,640 in the last quarter. 11.40% of the stock is owned by insiders.
Danaher stock traded up $0.21 during trading on Friday, hitting $139.63. The company had a trading volume of 2,297,201 shares, compared to its average volume of 2,145,888. Danaher Co. has a 1-year low of $94.59 and a 1-year high of $140.25. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.74 and a current ratio of 2.18. The company has a market capitalization of $99.97 billion, a PE ratio of 30.89, a price-to-earnings-growth ratio of 2.70 and a beta of 0.95.
Danaher (NYSE:DHR) last posted its earnings results on Thursday, April 18th. The conglomerate reported $1.07 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.01 by $0.06. Danaher had a net margin of 12.04% and a return on equity of 11.61%. The firm had revenue of $4.88 billion during the quarter, compared to the consensus estimate of $4.80 billion. During the same quarter last year, the firm earned $0.99 EPS. The firm’s revenue for the quarter was up 3.9% on a year-over-year basis. As a group, equities research analysts forecast that Danaher Co. will post 4.77 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be issued a $0.17 dividend. The ex-dividend date of this dividend is Thursday, June 27th. This represents a $0.68 annualized dividend and a yield of 0.49%. Danaher’s dividend payout ratio (DPR) is presently 15.04%.
DHR has been the topic of several analyst reports. Janney Montgomery Scott raised shares of Danaher from a “neutral” rating to a “buy” rating in a research report on Monday, February 25th. UBS Group lifted their price target on shares of Danaher from $125.00 to $144.00 and gave the company a “buy” rating in a research report on Tuesday, February 26th. Deutsche Bank lifted their price target on shares of Danaher to $130.00 and gave the company a “buy” rating in a research report on Tuesday, February 26th. Jefferies Financial Group lifted their price target on shares of Danaher to $140.00 and gave the company a “buy” rating in a research report on Tuesday, February 26th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $138.00 price target (up previously from $114.00) on shares of Danaher in a research report on Thursday, February 28th. Three investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $133.00.
WARNING: This article was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2019/06/16/danaher-co-nysedhr-shares-bought-by-marshall-wace-north-america-l-p.html.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Recommended Story: Producer Price Index (PPI)
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.